ASP Isotopes Inc. (ASPI) is a Dallas-based advanced materials company developing isotope enrichment technology — including its Aerodynamic Separation Process and Quantum Enrichment platforms — for medical, semiconductor and nuclear fuel markets, alongside helium and LNG operations tied to South Africa's Virginia Gas Project. On Tuesday morning, the stock changed hands at $1.4371, down 6.49% from the previous session's close of $1.54, confirming a clear downward move. The immediate cause was unambiguous: late Monday, the company reported third-quarter results that showed a sharply wider loss, a per-share miss and a credit-covenant default disclosure, and investors continued to sell into the new session.
The numbers drove the narrative. Revenue rose 303% year over year to $5.12 million from $1.27 million, but total operating expenses climbed to $41.31 million from $15.23 million, pushing the operating loss to $40.52 million from $14.99 million. Net loss more than doubled to $30.37 million, or $0.21 per share on a GAAP basis, from $12.62 million, or $0.14, a year ago. On an adjusted basis the loss reached $0.28 per share, well short of the roughly $0.13 loss analysts had modeled — a clear earnings miss that reset near-term expectations lower.
Buried in the quarterly filing was arguably the more consequential disclosure: Tetra4, the Virginia Gas Project operator, was in default under its DFC credit facility and not in compliance with IDC financial covenants as of September 30. The company warned that failing to secure amendments or waivers could accelerate outstanding principal and interest. Current debt rose to $47.69 million from $584,000 at year-end, while cash and equivalents declined to $201.66 million from $279.57 million and short-term investments fell to zero from $47.75 million. For a pre-commercial company funding an estimated $1.16 billion second phase, that combination weighs on sentiment.
ASP Isotopes has still not recognized revenue from the sale of enriched isotopes. Management is now pointing to initial silicon-28 shipments in the fourth quarter of 2026, with ytterbium-176 pushed into 2027 — a pattern of repeated timeline slippage that has eroded credibility over the past year. Shareholders have also absorbed substantial dilution, with the share count up sharply over the trailing year. A bright spot came from the radiopharmacy business, which generated $4.3 million of revenue and $1.6 million of gross profit at a 38% margin, up from 19%, and a third enrichment facility finished commissioning. The helium and LNG segment, however, posted a negative 96% gross margin as volumes remain too low to absorb fixed costs.
The move was company-specific rather than a sector or index event. Monday's session traded roughly 4.5 million shares, well above the recent pace of about two to three million, while Tuesday's opening volume was lighter. Technically, the picture is decisively weak: at $1.44 the stock sits about 43% below its 50-day moving average near $2.52 and has broken below its prior 52-week low of $1.66, a level that had held through the earlier November selloff. The stock is now down more than 60% year to date and roughly 90% from its October 2025 high of $14.49, a decline consistent with a speculative name repricing from story to execution risk. Despite that, the small analyst cohort tracked by the market maintains an average Buy rating and has not capitulated on long-term valuation.
The scale runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. The score here is 33 out of 100.
The verified news was substantive but not transformative relative to a company of this size: a wider quarterly loss, a per-share miss and a covenant default are material for a business that has yet to sell enriched isotopes commercially, yet they largely extend a narrative already reflected in the share price. The price move itself was modest by the stock's own standards — about 1.5 times its typical daily swing of 4.3%, with 17 of the past 60 sessions recording moves of equal or larger size. Weak news and an unremarkable move combine into a low-to-moderate score.
Attention shifts to execution on the fourth-quarter targets: initial silicon-28 shipments, a ramp of helium output toward nameplate capacity, and progress toward ytterbium-176 in 2027 under the multi-year HALEU supply agreements with TerraPower beginning in 2028. Investors will also watch for news on waivers or amendments from the DFC and IDC lenders, quarterly cash burn against management's stated 12-month-plus liquidity runway, and the next financial report expected in the first quarter of 2027. Risks include further milestone slippage, additional capital raising that dilutes existing holders, and any acceleration of debt obligations if covenant negotiations fail.
Trending AI Robots is a curated section of Tickeron's platform that surfaces the automated strategies performing best under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, and only the strongest performers earn a place in this featured list. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the page gives investors a practical way to compare live behaviour rather than theory. For readers weighing volatile names like ASPI, it is a useful starting point for research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ASPI saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 66 similar instances where the indicator turned negative. In 62 of the 66 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASPI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for ASPI entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ASPI's RSI Oscillator exited the oversold zone, 25 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for ASPI just turned positive on October 27, 2026. Looking at past instances where ASPI's MACD turned positive, the stock continued to rise in 28 of 29 cases over the following month. The odds of a continued upward trend are 90%.
Following a +24.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASPI advanced for three days, in 198 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
ASPI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.202) is normal, around the industry mean (2.284). P/E Ratio (-1.634) is within average values for comparable stocks, (-17.137). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.548). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (11.062) is also within normal values, averaging (48.960).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. ASPI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASPI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ChemicalsSpecialty